Journal of Biochemistry International

Protein kinases have been broadly considered as significant class of target in cancer therapeutics. The mammalian target of rapamycin (mTOR) belongs to a group of protein kinases regulating cell growth and protein synthesis. Rapamycin, a natural antifungal antibiotic, can that inhibit protein kinases by partner with its intracellular receptor FKBP12. The FKBP12-rapamycin complex ties straight forwardly to the FKBP12-Rapamycin Binding (FRB) space of mTOR. Side effects in patients consuming rapamycin include: severe mood swings, small purple spots over the body retention, face allergy and anxiety. Based on recent literatures, it is understood that drug like molecules from drug bank were used to screen for potential inhibitors by docking into the active site of mTOR. A few studies used in silico tool like GLIDE, which yielded useful information about several docked structures. The drug like molecules which were complexed with mTOR could be subjected to molecular simulation studies with molecules like DB00094, which was previously reported as fertility agent targeting follicle stimulating hormone receptor. Recent literature studies have demonstrated progress in identifying mTOR drug targets in treating lung cancers and in this paper we have updated the docking score methods using in silico tools.